This is unpublished
ARGX
Active Studies
Actively Enrolling
Transplantation
Pinned
Principal Investigator
Nicolae Leca, MD
Funding Agency
Sponsor: argenx BV
Status
Active
Actively Enrolling
Investigator
What is the argx Study?
A Global, Multicenter, Randomized, Double-Blinded, Placebo-
Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC Administered by a Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection
What are the criteria for the study?
This study includes kidney transplant recipients (aged 18–79) who can provide informed consent. Eligible participants must have undergone a transplant at least six months.
WHO DO I CONTACT FOR MORE INFORMATION?
Research Coordinator
Nidhi Mehta
E: nidhim3@Nephrology.washington.edu